Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that a drug registration application submitted by one of its subsidiaries has been accepted by the relevant regulatory authority. The company noted that the acceptance of the application is an early step in the regulatory process and emphasized that the drug is still subject to further requirements, including passing GMP compliance inspections and obtaining final drug registration approval before commercial production can commence. Fosun Pharma also noted that the acceptance of the application is not expected to have a material impact on the Group's results at this stage, and highlighted potential uncertainties related to future sales performance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260210-12020611), on February 10, 2026, and is solely responsible for the information contained therein.